これがあればCOVID-19用ｍRNAワクチンなんていらない

 

The closest thing to a COVID 'cure'? Eli Lilly's combination antibody drug cuts the risk of COVID-19 hospitalization and death by 87%, study finds

• The combination treatment, a mixture of two drugs, recognizes the coronavirus and attaches to it, preventing it from spreading throughout the body  
• Half a group of 769 mild-to-moderate COVID-19 patients at high risk of severe illness were given the drugs and another half given the placebo
• There four hospitalizations and zero deaths among the patients given the treatment and 11 hospitalizations and four deaths among the placebo group
• Researchers determined the combination therapy reduced the risk of hospitalization and death by 87 percent compared to a placebo
• Last month, the U.S. agreed to buy 100,000 doses of the antibody therapy, expected to be delivered by the end of the month, for $210 million

By Mary Kekatos Senior Health Reporter For Dailymail.com

Published: 15:57 EST, 10 March 2021 | Updated: 16:07 EST, 10 March 2021

https://www.dailymail.co.uk/health/article-9347813/Eli-Lillys-combination-antibody-therapy-COVID-19-cuts-risk-hospitalization-death-87.html 

Eli Lilly & Co says its combination antibody therapy is effective at treating mild to moderate cases of COVID-19. 

The treatment, a mixture of drugs bamlanivimab and etesevimab, was developed by Indianapolis-based Lilly and the Canadian company AbCellera. 

It recognizes the virus once a person is infected and attaches to it, preventing the pathogen from entering human cells, and therefore neutralizing it. 

In trial data released on Wednesday, Eli Lilly said the combination reduced the risk of hospitalization and death by 87 percent compared to a placebo. 

The results are an improvement of an earlier study of the combination, which reduced the risk of hospitalization and death by 70 percent. 

、、、（爆ｗｗｗｗｗｗｗｗｗｗｗｗｗ